Orexo Buying Biolipox

Orexo AB (STO: ORX) has agreed to acquire Biolipox AB, a Swedish drug company focused on therapies for inflammatory diseases, including pain management and respiratory diseases like asthma and chronic obstructive pulmonary disease. The all-stock deal is valued at approximately $134 million, or 8.56 million Orexo shares. Biolipox has raised around $60 million in VC funding from firms like HealthCap (24.4% ownership), Apax Partners (21.2%), Sofinnova Partners (19.9%), Scandinavian Life Science Venture (9.8%), Credit Agricole Private Equity (8.4%) and Auriga (6%). www.orexo.se www.biolipox.com